After finishing at $137.50 in the prior trading day, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $127.90, down -6.98%. In other words, the price has decreased by -$9.60 from its previous closing price. On the day, 2107816 shares were traded.
Ratios:
Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 5.44. In the meantime, Its Debt-to-Equity ratio is 1.79 whereas as Long-Term Debt/Eq ratio is at 1.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on January 31, 2024, initiated with a Outperform rating and assigned the stock a target price of $170.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $109.Deutsche Bank initiated its Buy rating on December 12, 2023, with a $109 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 03 when Barry Richard bought 50,000 shares for $78.81 per share. The transaction valued at 3,940,500 led to the insider holds 140,000 shares of the business.
INGRAM DOUGLAS S bought 25,225 shares of SRPT for $2,001,800 on Nov 03. The President & CEO now owns 390,307 shares after completing the transaction at $79.36 per share. On Aug 14, another insider, Chambers Michael Andrew, who serves as the Director of the company, bought 9,979 shares for $109.47 each. As a result, the insider paid 1,092,429 and bolstered with 246,996 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 12.86B and an Enterprise Value of 12.50B. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.83 while its Price-to-Book (P/B) ratio in mrq is 15.65. Its current Enterprise Value per Revenue stands at 11.31 whereas that against EBITDA is -21.02.
Stock Price History:
Over the past 52 weeks, SRPT has reached a high of $159.89, while it has fallen to a 52-week low of $55.25. The 50-Day Moving Average of the stock is 115.88, while the 200-Day Moving Average is calculated to be 112.01.
Shares Statistics:
The stock has traded on average 1.21M shares per day over the past 3-months and 1.02M shares per day over the last 10 days, according to various share statistics. A total of 93.55M shares are outstanding, with a floating share count of 88.00M. Insiders hold about 5.93% of the company’s shares, while institutions hold 86.50% stake in the company. Shares short for SRPT as of Feb 15, 2024 were 4.81M with a Short Ratio of 3.97, compared to 5.68M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.14% and a Short% of Float of 5.36%.
Earnings Estimates
Its stock is currently analyzed by 15 different market analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of $0.62 and a low estimate of -$4.04, while EPS last year was -$5.86. The consensus estimate for the next quarter is $0.26, with high estimates of $1.72 and low estimates of -$0.48.
Analysts are recommending an EPS of between $10.71 and -$0.63 for the fiscal current year, implying an average EPS of $2.53. EPS for the following year is $8.85, with 17 analysts recommending between $24.27 and -$1.1.
Revenue Estimates
12 analysts predict $398.73M in revenue for the current quarter. It ranges from a high estimate of $457.52M to a low estimate of $346M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $253.5M, an estimated increase of 57.30% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $431.45M, an increase of 65.20% over than the figure of $57.30% in the same quarter last year. There is a high estimate of $509.59M for the next quarter, whereas the lowest estimate is $380.2M.
A total of 23 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $3.11B, while the lowest revenue estimate was $1.55B, resulting in an average revenue estimate of $1.96B. In the same quarter a year ago, actual revenue was $1.24B, up 57.40% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $2.87B in the next fiscal year. The high estimate is $4.79B and the low estimate is $1.84B. The average revenue growth estimate for next year is up 46.50% from the average revenue estimate for this year.
